肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：一种新的治疗组合——NUC-1031联合卡铂治疗复发性卵巢癌

2021-03-21 MedSci原创 MedSci原创

卵巢癌卵巢癌肿瘤卵巢癌细胞复发性卵巢癌
关注

一种新的治疗组合——NUC-1031联合卡铂治疗复发性卵巢癌

NUC-1031是吉西他滨的一类前体肽修饰剂。 近日，英国牛津大学的Farasat Kazmi课题组对NUC-1031联合卡铂治疗复发性卵巢癌（OC）进行了IB期临床实验。 该研究NUC-1031于第1天和第8天给予卡铂，第1天每3周给药一次，共6个疗程。对NUC-1031（500,625,750mg/m2）与卡铂（AUC4,5）的4个剂量组进行了比较。主要终点为推荐的II期联合用药剂量（RP2CD）。次要终点包括安全性、研究者评估的客观有效率（ORR）、临床受益率（CBR）、无进展生存期（PFS）和药代动力学生存期（PK）。 如何确定RP2CD： 根据第一阶段研究的结果，选择月累计量（MTD）低于750mg/m2的剂量作为NUC-1031与卡铂AUC4联合的起始剂量。使用加速滴定方法在3至6名患者的队列中依次增加剂量，在每个计划队列中交替增加NUC-1031和卡铂。当最大耐受剂量（MTD）/RP2CD确定后，剂量增加停止。最大耐受剂量被定义为6名患者中不到2名（或<33%）出现剂量限制毒性的最高剂量水平。然后在MTD时对扩增队列进行给药，以确认RP2CD。 在25例复

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-10-26 ms3153534357578991

    #铂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-06-07 hb2008ye

    #复发性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-06-09 pandamao2018

    #治疗组#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    已看，还可以。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-03-25 ms7000000393543788

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-03-24 ms5000000518166734

    已读，真是受益匪浅呀！

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-03-22 windight

    #复发性卵巢癌#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1737687, encodeId=3abb1e376878e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Oct 26 01:38:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909887, encodeId=b0de190988e75, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Jun 07 07:38:14 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654936, encodeId=32ef165493659, content=<a href='/topic/show?id=91af64690a7' target=_blank style='color:#2F92EE;'>#治疗组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64690, encryptionId=91af64690a7, topicName=治疗组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd5124580215, createdName=pandamao2018, createdTime=Wed Jun 09 21:38:14 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954936, encodeId=239f95493610, content=已看，还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:21:38 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950945, encodeId=70e49509450d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb8f5459361, createdName=ms7000000393543788, createdTime=Thu Mar 25 10:39:29 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950612, encodeId=6d629506122b, content=已读，真是受益匪浅呀！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Mar 24 07:58:59 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349633, encodeId=d20b134963373, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Mar 22 15:38:14 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-03-22 智者为医08

    #卡铂#

    0

相关资讯

Nat Commun：CAR-T细胞通过介导免疫抑制性肿瘤相关巨噬细胞的耗竭增强免疫疗法的疗效

免疫抑制性肿瘤微环境（TME）是肿瘤特异性T细胞对癌症有效反应的主要障碍。

Eur Radiol：卵巢肿瘤MRI诊断知多少？

卵巢癌在影像学图像上通常表现为肿块样病变，但部分卵巢肿瘤表现为非肿块形，良恶性病变在影像学表现上有所交叉，因此准确区分卵巢良恶性病变对于指导患者的进一步治疗至关重要。

SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！

奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异

上皮性卵巢癌化疗和PARPi治疗相关血液学毒副作用：临床表现，诊断和管理

上皮性卵巢癌（EOC）是女性中第五大最常见的癌症，是妇科恶性肿瘤中致死率最高的肿瘤，确诊时通常已是晚期。手术后进行铂类化疗仍然是金标准治疗。但是，大多数患者会复发，在最近几年中，多聚-ADP-核糖聚合

JAMA Netw Open：乳腺癌和卵巢癌患者致癌变异的携带情况

遗传性乳腺癌和卵巢癌综合征相关基因的有害变异是否与说英语和克里奥尔语的加勒比海人群中乳腺癌和卵巢癌的发生有关？

Lancet Oncol：复旦中山医院证实复发卵巢癌的二次手术价值！有望改写指南！（SOC-1研究）

2020年ASCO大会上，复旦大学附属中山医院臧荣余教授首次在口头报告专场公布了SOC-1研究的结果。与德国III期DESKTOP研究互相印证，SOC-1研究再次证实，二次肿瘤细胞减灭术可为铂敏感复发

拓展阅读

J Clin Oncol：二次细胞减灭术对铂敏感的复发性卵巢癌患者生存期的影响

二次细胞减灭术可最大限度地切除肿瘤，显著延长铂敏感的复发性卵巢癌患者的总生存时间

JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？

复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？

Lancet oncol：二次减瘤术对于铂敏感的复发性卵巢癌到底有无益处？

中国人自己的数据~

ESMO Open：西地尼布联合化疗治疗复发性卵巢癌的3期试验结果

西地尼布（Cediranib）是一种口服的抗血管生成的VEGF受体1-3抑制剂

Br J Cancer：贝洛替康与拓扑替康治疗复发性卵巢癌的2b期临床研究

研究显示，卵巢癌的预后较差，目前确诊的三分之二以上的患者已处于IIIC–IV期，且患者的5年生存率<30％。

Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析

在ARIEL3试验（评估PARP抑制剂rucaparib用于复发性卵巢癌）中，rucaparib维持治疗可较安慰剂显著提高患者的无进展存活期。现Ledermann等人将预先确定的、研究者评估的、探索性